Capital remains selective in ‘barbell’ biotech market
· marian chu
AI Briefing
- • Biotech investment sector shows signs of recovery in Asia.
- • Capital flows selectively to companies with clinical differentiation.
- • Strong management teams and commercialization paths are key priorities.
Source Summary
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that can demonstrate clinical differentiation, strong management teams and a clear path to commercialization.
Advertisement